EnGene Fiscal 2025 Loss Widens

MT Newswires Live2025-12-23

EnGene (ENGN) reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.

Analysts polled by FactSet expected a loss of $2.10.

Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.

Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.

The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593530564?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593530564","market":"sg","top_or_hot":-1,"title":"EnGene Fiscal 2025 Loss Widens","media":"MT Newswires Live","content":"<html><body><p> EnGene (ENGN) reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.</p><p>Analysts polled by FactSet expected a loss of $2.10.</p><p>Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.</p><p>Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.</p><p>The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EnGene Fiscal 2025 Loss Widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnGene Fiscal 2025 Loss Widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 06:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> EnGene (ENGN) reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.</p><p>Analysts polled by FactSet expected a loss of $2.10.</p><p>Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.</p><p>Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.</p><p>The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENGN","symbol_name":"ENGENE HOLDINGS INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593530564","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593530564","pubTimestamp":1766441578,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"EnGene  reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.Analysts polled by FactSet expected a loss of $2.10.Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ENGN":"ENGENE HOLDINGS INC","BK4139":"生物科技"},"translate_title":"Engene 2025财年亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENGN":1},"content_text":"EnGene (ENGN) reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.Analysts polled by FactSet expected a loss of $2.10.Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593530564","isCrawlerRequest":true}